CAJ | 학술논문

目的研究沙格雷酯在预防外周动脉支架术后支架内再狭窄( in-stent restenosis,ISR)中的治疗效果.方法对因外周血管狭窄或闭塞行首次支架术治疗的患者68例分为2组,沙格雷酯组:口服沙格雷酯+阿司匹林；双抗组:口服氯吡格雷+阿司匹林.术后即开始分组治疗,6个月后复查血管彩超,比较2组患者支架内再狭窄的发生情况.结果试验共完成随访62例患者.沙格雷酯组和双抗组各病变部位的狭窄率分别为7.0％比18.1％ (P =0.036),平均峰值流速比(peaksystolic velocity ratio,PSVR)分别为1.34比2.08(P=0.010),ISR发生例数为1比10 (P =0.005),差异均有统计学意义.所有随访患者均未观察到严重不良事件.结论沙格雷酯与阿司匹林联用,安全有效.沙格雷酯+阿司匹林与双抗治疗相比,可以显著降低外周动脉支架术后的再狭窄发生率,同时显著减少支架内内膜增殖.
목적 연구사격뢰지재예방외주동맥지가술후지가내재협착( in-stent restenosis,ISR)중적치료효과.방법 대인외주혈관협착혹폐새행수차지가술치료적환자68례분위2조,사격뢰지조:구복사격뢰지+아사필림；쌍항조:구복록필격뢰+아사필림.술후즉개시분조치료,6개월후복사혈관채초,비교2조환자지가내재협착적발생정황.결과 시험공완성수방62례환자.사격뢰지조화쌍항조각병변부위적협착솔분별위7.0％비18.1％ (P =0.036),평균봉치류속비(peaksystolic velocity ratio,PSVR)분별위1.34비2.08(P=0.010),ISR발생례수위1비10 (P =0.005),차이균유통계학의의.소유수방환자균미관찰도엄중불량사건.결론 사격뢰지여아사필림련용,안전유효.사격뢰지+아사필림여쌍항치료상비,가이현저강저외주동맥지가술후적재협착발생솔,동시현저감소지가내내막증식.
Objective To evaluate the impact of sarpogrelate on the in-stent restenosis (ISR) after percutaneous transluminal angioplasty (PTA) in peripheral arterial diseases (PAD).Methods PAD patients who had PTA for the first time were divided into two groups receiving respectively clopidogrel and aspirin (clopidogrel group) or sarpogrelate and aspirin (sarpogrelate group).Vascular ultrasonography was performed at 6 months after PTA in all patients to evaluate the degree of ISR.Results 62 patients finished the follow-up visits as required.The in-stent restenosis in the sarpogrelate group and clopidogrel group was 7.0％ vs.18.1％ (P =0.036),the peak systolic velocity ratio was 1.34 vs.2.08 (P =0.010) and the cases of ISR was 1 vs.10 (P =0.005) respectively.No patients reported serious adverse events.Conclusions Sarpogrelate combined with aspirin is safe and effective.Compare with clopidogrel and aspirin,sarpogrelate and aspirin can significantly reduce the rate of ISR after PTA and the intimal proliferation in the stent.